

G9/1757

DOCKET No.: CARR-0084  
(103216.00252)

PATENT  
RECEIVED

NOV 25 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900



Applicant: Yawei Ni, et al.

Serial No.: 10/059,627

Filed: January 29, 2002

Group: 1751

For: COMBINATION OF A GROWTH FACTOR AND A PROTEASE ENZYME

RECEIVED


NOV 21 2002

TC 1700

#5  
M.G.J  
12/5/02

Commissioner of Patents  
Washington, D. C. 20231


Sir:



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, which ever event occurs last. 37 C.F.R. § 1.97(b).

Respectfully submitted,  
JACKSON WALKER L.L.P.

  
T. Ling Chwang  
Registration No. 33,590

Dated: November 15, 2002

JACKSON WALKER L.L.P.  
2435 North Central Expressway, Suite 600  
Richardson, Texas 75080  
Tel: (972) 744-2919  
Fax: (972) 744-2909

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

NOV 25 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

| Complete if Known      |                          |
|------------------------|--------------------------|
| Application Number     | 10/059,627               |
| Filing Date            | January 29, 2002         |
| First Named Inventor   | Yawei Ni, et al.         |
| Group Art Unit         | 1751                     |
| Examiner Name          | unknown                  |
| Attorney Docket Number | CARR-0084 (103216.00252) |

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     | B1                    | AARONSON, STUART A., ET AL., "Keratinocyte Growth Factor. A Fibroblast Growth Factor Family Member with Unusual Target Cell Specificity", Annals of the New York Academy of Sciences, 1991, Vol. 638, Pages 62-77   |                |
|                     | B2                    | BAJAJ-ELLIOTT, MONA, ET AL., "Keratinocyte Growth Factor in Inflammatory Bowel Disease. Increased mRNA Transcripts in Ulcerative Colitis Compared with Crohn's Disease in Biopsies and Isolated Mucosal Myofibroblasts", American Journal of Pathology, November 5, 1997, Vol. 151 (No. 5), Pages 1469-1476 |                |
|                     | B3                    | BASKIN, LAURENCE S., ET AL., "Growth Factors in Bladder Wound Healing", Journal of Urology, June 1997, Vol. 157, Pages 2388-2395  |                |
|                     | B4                    | BECHTEL, MICHAEL J., ET AL., "Upregulation of Cell-Surface-Associated Plasminogen Activation in Cultured Keratinocytes by Interleukin-1 $\beta$ and Tumor Necrosis Factor- $\alpha$ ", Experimental Cell Research, 1996, Vol. 223, Pages 395-404  |                |
|                     | B5                    | BEER, HANS-DIETMAR, ET AL., "Mouse Fibroblast Growth Factor 10: cDNA Cloning, Protein Characterization and Regulation of mRNA Expression", Oncogene, 1997, Vol. 15, Pages 2211-2218   |                |
|                     | B6                    | BELLOSTA, P, ET AL., "Cleavage of K-FGF Produces a Truncated Molecule with Increased Biological Activity and Receptor Binding Affinity", Journal of Cell Biology, 1993, Vol. 121, Pages 705-713   |                |
|                     | B7                    | BUGGE, THOMAS H., ET AL., "Loss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency", Cell, 1996, Vol. 87, Pages 709-719  |                |
|                     | B8                    | CARMELIET, PETER, ET AL., "Genetic Analysis of Blood Vessel Formation Role of Endothelial Versus Smooth Muscle Cells", Trends in Cardiovascular Medicine, 1997, Vol. 7, Pages 271-281   |                |
|                     | B9                    | CARMELIET, PETER, ET AL., "Inhibitory Role of Plasminogen Activator Inhibitor-1 in Arterial Wound Healing and Neointima Formation - A Gene Targeting and Gene Transfer Study in Mice". Circulation, 1997, Vol. 96, Pages 3180-3191  |                |
|                     | B10                   | CARMELIET, PETER, ET AL., "Development and Disease in Proteinase-Deficient Mice: Role of the Plasminogen, Matrix Metalloproteinase and Coagulation System", Thrombosis Research, 1998, Vol. 91, Pages 255-285   |                |
|                     | B11                   | CHEDID, MARCIO, ET AL., "Glucocorticoids Inhibit Keratinocyte Growth Factor Production in Primary Dermal Fibroblasts", Endocrinology, 1996, Vol. 137, Pages 2232-2237   |                |
|                     | B12                   | COLLEN, DESIRE, ET AL., "Fibrinolysis and the Control of Hemostasis", The Molecular Basis of Blood Diseases, Ed. G. S. Stamatoyannopoulos, A. W. Nienhuis, P. W. Majerus, and H. Varmus. Philadelphia: W. B. Saunders Co., 1994, Pages 725-752  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |   |                          |                          |
|---|---|--------------------------|--------------------------|
| Substitute for form 1449A/PTO   |   | <b>Complete if Known</b> |                          |
|   |   | Application Number       | 10/059,627               |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | Filing Date              | January 29, 2002         |
|   |   | First Named Inventor     | Yawei Ni, et al.         |
|   |   | Group Art Unit           | 1751                     |
|   |   | Examiner Name            | unknown                  |
|   |   | Attorney Docket Number   | CARR-0084 (103216.00252) |
| Sheet   | 3 | of                       | 6                        |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|  | B13                   | COLLEN, DESIRE, "The Plasminogen (Fibrinolytic) System", Thrombosis and Haemostasis, 1999, Vol. 82, Pages 259-270   |                |
|  | B14                   | FARRELL, CATHERINE L., ET AL., "Keratinocyte Growth Factor Protects Mice from Chemotherapy and Radiation-induced Gastrointestinal Injury and Mortality", Cancer Research, 1998, Vol. 58, Pages 933-939  |                |
|  | B15                   | FEHRENBACH, H., ET AL., "Keratinocyte Growth Factor-induced HyperPlasia of Rat Alveolar Type II Cells in Vivo is Resolved by Differentiation into Type I Cells and by Apoptosis", European Respiratory Journal, 1999, Vol. 14, Pages 534-544                    |                |
|  | B16                   | FINCH, PAUL W., ET AL., "Human KGF Is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth", Science, 1989, Vol. 245, Pages 752-755  |                |
|  | B17                   | FOLKMAN, JUDAH, "Seminars in Medicine of the Beth Israel Hospital, Boston, Clinical Applications of Research of Angiogenesis", New England Journal of Medicine, 1995, Vol. 333, Pages 1757-1763   |                |
|  | B18                   | GILLIS, PAUL, ET AL., Keratinocyte Growth Factor Induces Angiogenesis and Protects Endothelial Barrier Function", Journal of Cell Science, 1999, Vol. 112, Pages 2049-2057  |                |
|  | B19                   | HELISCH, ARMIN, ET AL., Therapeutic Angiogenesis in Ischemic Heart Disease", Thrombosis and Haemostasis, 1999, Vol. 82, Pages 772-780   |                |
|  | B20                   | HEYMANS, S., ET AL., "Inhibition of Plasminogen Activators or Matrix Metalloproteinases Prevents Cardiac Rupture but Impairs Therapeutic Angiogenesis and Causes Cardiac Failure", Nature Medicine, 1999, Vol. 5, Pages 1135-1142                               |                |
|  | B21                   | HIRAOKA, NOBUAKI, ET AL., "Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins", Cell, 1998, Vol. 95, Pages 365-377   |                |
|  | B22                   | HOFFMAN, RICHARD, ET AL., "Wound Fluid from Venous Leg Ulcers Degrades Plasminogen and Reduces Plasmin Generation by Keratinocytes", Journal of Investigative Dermatology, 1998, Vol. 111, Pages 1140-1144  |                |
|  | B23                   | IGARASHI, MAKOTO, ET AL., "Characterization of Recombinant Human Fibroblast Growth Factor (FGF)-10 Reveals Functional Similarities with Keratinocyte Growth Factor (FGF-7)", The Journal of Biological Chemistry, 1998, Vol. 273, Pages 13230-13235             |                |
|  | B24                   | JIMENEZ, PABLO A., ET AL., "Keratinocyte Growth Factor-2 Accelerates Wound Healing in Incisional Wounds", Journal of Surgical Research, 1999, Vol. 81, Pages 238-242  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

| Compleat if Known      |                          |
|------------------------|--------------------------|
| Application Number     | 10/059,627               |
| Filing Date            | January 29, 2002         |
| First Named Inventor   | Yawei Ni, et al.         |
| Group Art Unit         | 1751                     |
| Examiner Name          | unknown                  |
| Attorney Docket Number | CARR-0084 (103216.00252) |

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     | B25                   | JOHNSON, DANIEL E., ET AL., "Structural and Functional Diversity in the FGF Receptor Multigene Family", Advances in Cancer Research, 1993, Vol. 60, Pages 1-41  |                |
|                     | B26                   | KAO, WINSTON W., ET AL., "Healing of Corneal Epithelial Defects in Plasminogen-and-Fibrinogen-Deficient Mice", Investigative Ophthalmology & Visual Science, 1998, Vol. 39, Pages 502-508   |                |
|                     | B27                   | KOMOROWIEZ, ERZSEBET, ET AL., "Fibrinolysis with Des-Kringle Derivatives of Plasmin and its Modulation by Plasma Protease Inhibitors", Biochemistry, 1998, Vol. 37, Pages 9112-9118   |                |
|                     | B28                   | LU, WEIQIN, ET AL., "Fibroblast Growth Factor-10. A Second Candidate Stromal to Epithelial Cell Andromedin in Prostate", The Journal of Biological Chemistry, 1999, Vol. 274, Pages 12827-12834   |                |
|                     | B29                   | LUND, LEIF R., ET AL., "Functional Overlap between Two Classes of Matrix-degrading Proteases in Wound Healing", The European Molecular Biology Organization Journal, 1999, Vol. 18, Pages 4645-4656   |                |
|                     | B30                   | MARCHESE, CINZIA, ET AL., "Modulation of Keratinocyte Growth Factor and its Receptor in Reepithelializing Human Skin", Journal of Experimental Medicine, 1995, Vol. 182, Pages 1369-1376  |                |
|                     | B31                   | MCKEEHAN, WALLACE L., ET AL., "The Heparan Sulfate-Fibroblast Growth Factor Family: Diversity of Structure and Function", Progress in Nucleic Acid Research & Molecular Biology, 1998, Vol. 59, Pages 135-176   |                |
|                     | B32                   | MORIKOA, SHINJI, ET AL., "Migrating Keratinocytes Express Urokinase-Type Plasminogen Activator", Journal of Investigative Dermatology, 1987, Vol. 88, Pages 418-423   |                |
|                     | B33                   | ODEKON, LALE E., ET AL., "Requirement for Receptor-Bound Urokinase in Plasmin-Dependent Cellular Conversion of Latent TGF-β to TGF-β", Journal of Cellular Physiology, 1994, Vol. 158, Pages 398-407  |                |
|                     | B34                   | OSSLUND, TIMOTHY D., ET AL., "Correlation Between the 1.6 Angstrom Crystal Structure and Mutational Analysis of Keratinocyte Growth Factor", Protein Science, 1998, Vol. 7, Pages 1681-1690   |                |
|                     | B35                   | ROMER, JOHN, ET AL., "The Receptor for Urokinase-type Plasminogen Activator is Expressed by Keratinocytes at the Leading Edge During Re-Epithelialization of Mouse Skin Wounds", Journal of Investigative Dermatology, 1994, Vol. 102, Pages 519-522            |                |
|                     | B36                   | ROMER, JOHN, ET AL., "Impaired Wound Healing in Mice with a Disrupted Plasminogen Gene", Nature Medicine, 1996, Vol. 2, Pages 287-292   |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6

**Complete if Known**

|                        |                          |
|------------------------|--------------------------|
| Application Number     | 10/059,627               |
| Filing Date            | January 29, 2002         |
| First Named Inventor   | Yawei Ni, et al.         |
| Group Art Unit         | 1751                     |
| Examiner Name          | unknown                  |
| Attorney Docket Number | CARR-0084 (103216.00252) |

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     | B37                   | RON, DINA, ET AL., "Expression of Biologically Active Recombinant Keratinocyte Growth Factor. Structure/Function Analysis of Amino-Terminal Truncation Mutants", Journal of Biological Chemistry, 1993, Vol. 268, Pages 2984-2988                               |                |
|                     | B38                   | RUBIN, JEFFREY S., ET AL., "Purification and Characterization of a Newly Identified Growth Factor Specific for Epithelial Cells", Proceedings of the National Academy of Sciences of the United States of America, 1989, Vol. 86, Pages 802-806                 |                |
|                     | B39                   | SALVA, USHMA, ET AL., "Barrier Function of Airway Epithelium: Effects of Radiation and Protection by Keratinocyte Growth Factor", Radiation Research, 1998, Vol. 150, Pages 195-203   |                |
|                     | B40                   | SCHLESSINGER, JOSEPH, ET AL., "Regulation of Growth Factor Activation by Proteoglycans: What is the Role of the Low Affinity Receptors?", Cell, November 3, 1995, Vol. 83, Pages 357-360  |                |
|                     | B41                   | STAIANO-COICO, LISA, ET AL., Human Keratinocyte Growth Factor Effects in a Porcine Model of Epidermal Wound Healing", Journal of Experimental Medicine, 1993, Vol. 178, Pages 865-878   |                |
|                     | B42                   | TAGASHIRA, SHUZO, ET AL., "Cloning of Mouse FGF10 and Up-Regulation of Its Gene Expression During Wound Healing", Gene, 1997, Vol. 197, Pages 399-404   |                |
|                     | B43                   | TSUBOI, RYOJI, ET AL., "Keratinocyte Growth Factor (FGF-7) Stimulates Migration and Plasminogen Activator Activity of Normal Human Keratinocytes", Journal of Investigative Dermatology, 1993, Vol. 101, Pages 49-53  |                |
|                     | B44                   | VAN SETTEN, GYSBERT-BOTHO, ET AL., "Plasmin and Plasminogen Activator Activities in Tear Fluid During Corneal Wound Healing after Anterior Keratectomy", Current Eye Research, 1989, Vol. 8, Pages 1293-1298  |                |
|                     | B45                   | WEISSMAN, BERNARD E., ET AL., "BALB and Kirsten Murine Sarcoma Viruses alter Growth and Differentiation of EGF-Dependent BALB/c Mouse Epidermal Keratinocyte Lines", Cell, 1983, Vol. 32, Pages 599-606   |                |
|                     | B46                   | WERNER, SABINE, ET AL., "Large Induction of Keratinocyte Growth Factor Expression in the Dermis during Wound Healing", Proceedings of the National Academy of Sciences of the United States of America, 1992, Vol. 89, Pages 6896-6900                          |                |
|                     | B47                   | WERNER, SABINE, ET AL. "The Function of KGF in Morphogenesis of Epithelium and Reepithelialization of Wounds", Science, 1994, Vol. 266, Pages 819-822   |                |
|                     | B48                   | WERNER, SABINE, "Keratinocyte Growth Factor: A Unique Player in Epithelial Repair Processes", Cytokine & Growth Factor Reviews, 1998, Vol. 9, Pages 153-165   |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
NOV 25 2002  
TECH CENTER 1600/2900

RECEIVED



+

RECEIVED  
NOV 21 2002

|   |   |                          |                  |                        |                          |
|---|---|--------------------------|------------------|------------------------|--------------------------|
| Institute for form 1449A/PTO  |   | <b>Complete if Known</b> |                  |                        |                          |
|   |   | Application Number       | 10/059,627       |                        |                          |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | Filing Date              | January 29, 2002 |                        |                          |
|   |   | First Named Inventor     | Yawei Ni, et al. |                        |                          |
|   |   | Group Art Unit           | 1751             |                        |                          |
|   |   | Examiner Name            | unknown          |                        |                          |
| Sheet   | 6 | of                       | 6                | Attorney Docket Number | CARR-0084 (103216.00252) |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|--|--------------------------|---|----------------|
| Examiner<br>Initials *                             | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|  | B49                      | WU, LIANCUN, ET AL., "Keratinocyte Growth Factor Induces Granulation Tissue in Ischemic Dermal Wounds. Importance of Epithelial-Mesenchymal Cell Interactions", Archives of Surgery, 1996, Vol. 131, Pages 660-666  |                |
|  | B50                      | YAMASAKI, MASAHIRO, ET AL., "Structure and Expression of the Rat mRNA Encoding a Novel Member of the Fibroblast Growth Factor Family", Journal of Biological Chemistry, 1996, Vol. 271, Pages 15918-15921   |                |
|  | B51                      | ZEEH, JORG M., ET AL., "Keratinocyte Growth Factor Ameliorates Mucosal Injury in an Experimental Model of Colitis in Rats, Gastroenterology, 1996, Vol. 110, Pages 1077-1083  |                |
|  | B52                      | ZHENG, JIE, ET AL., "Keratinocyte Growth Factor Enhances Urokinase-Type Plasminogen Activator Activity in HPV16 DNA-Immortalized Human Uterine Exocervical Epithelial Cells", 1996, European Journal of Cell Biology, 1996, Vol. 69, Pages 128-134              |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |
|  |                          |   |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+